Related by context. All words. (Click for frequent words.) 77 MAGE A3 ASCI 76 recurrent glioblastoma multiforme 75 YONDELIS 75 alkylating agent 75 thalidomide Thalomid 75 PSMA ADC 75 CYT# potent vascular disrupting 75 plasma kallikrein inhibitor 74 sorafenib Nexavar 74 AEG# 74 Aflibercept 74 receptor tyrosine kinase inhibitor 74 liposomal doxorubicin 74 riociguat 74 ELACYT 74 relapsed MM 74 fosbretabulin 74 ZOLINZA 74 pertuzumab 74 tanespimycin 73 pegylated liposomal doxorubicin 73 galiximab 73 Degarelix 73 Xelox 73 mapatumumab 73 verteporfin 73 enzastaurin 73 elotuzumab 73 vapreotide acetate 73 Azedra 73 denileukin diftitox 73 gemcitabine Gemzar 73 Temsirolimus 73 metastatic malignant 73 Doxil ® 73 Fludara ® 73 Pemetrexed 73 erlotinib Tarceva ® 73 sunitinib Sutent 72 bevacizumab Avastin ® 72 vorinostat 72 selective modulator 72 gefitinib Iressa 72 Vidaza azacitidine 72 adalimumab Humira 72 alvespimycin 72 kidney urologic 72 erythropoietic 72 neratinib 72 phase IIb trial 72 forodesine 72 Imprime PGG 72 PKC# 72 erlotinib Tarceva 72 histone deacetylase inhibitor 72 sorafenib tablets 72 mycophenolate mofetil 72 5 Fluorouracil 72 busulfan 72 Xanafide 72 interferon gamma 1b 72 corticosteroid dexamethasone 72 thetreatment 72 oral prodrug 72 TG# [003] 72 Lenocta 72 Velcade bortezomib 72 lenalidomide dexamethasone 72 cisplatin gemcitabine 72 targeted radiotherapeutic 72 radiation sensitizer 72 trial evaluating PRX# 72 antiangiogenic therapy 72 adecatumumab 71 potent antiproliferative 71 myelofibrosis polycythemia vera 71 IMA# 71 estramustine 71 Cloretazine 71 IAP inhibitor 71 FUSILEV enhances 71 cediranib 71 refractory chronic lymphocytic 71 dexamethasone Decadron 71 docetaxel Taxotere ® 71 HGS ETR2 71 evaluating tivozanib 71 demonstrated antitumor activity 71 Squalamine 71 CIMZIA ™ 71 Traficet EN 71 Panzem R NCD 71 paclitaxel Taxol ® 71 ZACTIMA 71 ENMD # 71 cilengitide 71 interleukin IL -# 71 novel VDA molecule 71 EOquin TM 71 Fulvestrant 71 SPRYCEL ® 71 GAMMAGARD 71 Aplidin 71 Irinotecan 71 CIMZIA TM 71 Amrubicin 71 gemcitabine cisplatin 71 mertansine 71 Thalomid ® 71 pomalidomide 71 cleavable linker 71 standard chemotherapy regimen 71 gadobutrol 71 PhG alpha 1 71 lenalidomide Revlimid R 71 HGS# 71 vidofludimus 71 Dasatinib 71 APTIVUS r 71 histone deacetylase HDAC inhibitor 71 PEG SN# 71 brivanib 71 Gliadel Wafer 71 cetuximab Erbitux R 71 Granulocyte Colony Stimulating Factor 71 sitaxsentan 71 haematologic 71 proteasome inhibitor 71 depsipeptide 71 CTAP# Capsules 71 brivaracetam 71 paclitaxel cisplatin 71 HER2 positive metastatic breast 71 ORENCIA R 71 CIMZIA TM certolizumab pegol 71 Trofex 71 TNF antagonist 71 OHR/AVR# 71 antiangiogenic agent 71 Azacitidine 71 cisplatin chemotherapy 71 Aliskiren 71 docetaxel Taxotere 71 Phase #b/#a clinical 71 Epratuzumab 71 CLORETAZINE TM VNP#M 71 Vidaza ® 71 ELOXATIN 71 pan HDAC inhibitor 71 fluoropyrimidine 71 Fludara 71 sunitinib malate 71 Folfox 71 hyaluronidase enzyme 71 Neulasta ® 71 Amplimexon 71 Platinol ® cisplatin 71 fallopian tube cancers 71 trastuzumab Herceptin ® 70 goserelin 70 XmAb# 70 ALN HPN 70 trabectedin 70 DOXIL 70 superficial bladder cancer 70 Enzastaurin 70 SNT MC# 70 Vandetanib 70 metaglidasen 70 tarenflurbil 70 gamma secretase inhibitor 70 Teriflunomide 70 Darinaparsin 70 palifermin 70 somatostatin analog 70 immunomodulatory therapy 70 sipuleucel T 70 #I TM# 70 INSPIRE Trial Phase III 70 hyperphenylalaninemia HPA due 70 antibody MAb 70 beta 1a 70 papillary renal cell carcinoma 70 flavopiridol 70 HuMax EGFr 70 Mitoxantrone 70 radiolabeled TM# 70 Tumor Response 70 HuLuc# 70 dasatinib Sprycel ® 70 immune modulating 70 Neulasta R 70 liposomal formulation 70 Sudhir Agrawal D.Phil 70 hA# 70 low dose cytarabine 70 ixabepilone 70 complement inhibitor eculizumab 70 TORISEL 70 orally administered inhibitor 70 OXi# 70 pain palliation 70 multicenter Phase II 70 trans retinoic acid 70 p# MAP kinase inhibitor 70 p# biomarker 70 Deforolimus 70 Platinol ® 70 Tarceva TM 70 CA4P 70 monoclonal antibody conjugated 70 epoetin alpha 70 oxaliplatin Eloxatin 70 CANCIDAS 70 lymphoid malignancies 70 colorectal carcinoma 70 SYN# 70 teriflunomide 70 Methylnaltrexone 70 murine model 70 Taxotere chemotherapy 70 panitumumab Vectibix 70 induced macular edema 70 HIF PH inhibitors 70 azacytidine 70 cytokine refractory 70 acetonide FA 70 BRAF inhibitor 70 ara C 70 pharmacodynamic PD 70 Phase Ib II 70 trastuzumab Herceptin R 70 chemoradiation therapy 70 GW# [003] 70 lexidronam injection 70 bortezomib Velcade R 70 Zolinza 70 IMC A# 70 Telintra 70 FOLFOX6 chemotherapy regimen 70 paclitaxel Taxol R 70 visilizumab 70 VNP#M 70 microtubule inhibitor 70 vernakalant hydrochloride 70 leukemia AML 70 5 FU leucovorin 70 BRIM2 70 mGluR2 NAM 70 Sapacitabine 70 Onconase 70 vinca alkaloid 69 huN# DM1 69 epithelial tumors 69 Aplidin R 69 Phase Ib clinical 69 anti EGFR antibody 69 HER2 overexpression 69 adjuvant radiotherapy 69 nab paclitaxel 69 Cardiotoxicity 69 Natalizumab 69 antitumor effect 69 cisplatin resistant 69 antitumor effects 69 Gleevec resistant 69 EFAPROXYN 69 Seliciclib 69 K ras mutations 69 Dacogen decitabine 69 ThermoDox R 69 posaconazole 69 Apoptone 69 chemotherapy FOLFOX 69 Triapine R 69 biologic DMARD 69 taxane resistant 69 Romiplostim 69 Bezielle 69 metastatic colorectal 69 HCD# [002] 69 ORENCIA ® 69 Chemophase 69 targeted antifolate 69 PNP inhibitor 69 recurrent GBM 69 FOLFOX chemotherapy 69 antiproliferative effects 69 weekly subcutaneous injections 69 Bortezomib 69 INCB# [001] 69 etanercept Enbrel 69 prostanoid 69 Ranolazine 69 trastuzumab DM1 T DM1 69 KRAS mutations occur 69 topoisomerase II inhibitor 69 NOD SCID mice 69 Interferon Beta 69 VAPRISOL 69 BrachySil TM 69 Pertuzumab 69 aripiprazole Abilify 69 cisplatin vinorelbine 69 gallium nitrate 69 trastuzumab Herceptin 69 PRT# 69 selective inhibition 69 rFVIIa 69 Tyrima 69 ritonavir boosted 69 Pivotal Phase III 69 chemotherapeutic drug 69 zoledronate 69 HDAC Inhibitor 69 antiangiogenic 69 Vaprisol 69 sargramostim 69 humanised monoclonal antibody 69 relapsing remitting MS RRMS 69 bortezomib Velcade 69 Hedgehog Pathway Inhibitor 69 GRNVAC1 69 PXD# 69 PDE4 inhibitor 69 antimetabolite 69 intratumoral injection 69 abacavir Ziagen 69 Hsp# Inhibitor 69 TIMP 1 69 cMET 69 mecamylamine 69 HGS ETR1 69 Solazed 69 favorable pharmacokinetic profile 69 Symadex 69 refractory prostate cancer 69 GRN# 69 Epidermal Growth Factor Receptor 69 huC# DM4 69 Lixivaptan 69 chemoembolization 69 Meets Primary Endpoint 69 Zybrestat 69 generation purine nucleoside 69 HGS ETR1 mapatumumab 69 recurrent glioma 69 paricalcitol 69 docetaxel Taxotere R 69 TNF Tumor Necrosis Factor 69 potent cytotoxic 69 Adenoscan R 69 TLK# 69 desvenlafaxine succinate 69 OMP #R# 69 alefacept 69 Archexin 69 receptor inhibitor 69 including eniluracil ADH 69 infusional 5-FU/LV 69 postoperative chemotherapy 69 HDL Selective Delipidation 69 Hepatocellular Carcinoma HCC 69 Tamibarotene 69 Leukine ® 69 QT QTc 69 IRX 2 69 Acute Ischemic Stroke 69 tumorigenicity 69 polycythemia vera PV 69 Pegylated Interferon 69 Omacetaxine 69 HQK 69 Phase III Pivotal 69 Decitabine 69 mTOR inhibitors 69 isoproterenol 69 IGF 1R inhibitor 69 Myocet 69 DAVANAT 69 TRAIL R1 69 multi kinase inhibitor 69 vWF 69 Cutaneous T 69 fluvastatin 69 myelodysplastic myeloproliferative diseases 69 GRNCM1 69 PrevOnco ™ 69 bendamustine 69 Panzem NCD 69 thymalfasin 69 Antitumor Activity 69 PEG IFN 69 pregabalin Lyrica 69 PD LID 69 bevacizumab Avastin R 69 phase IIb clinical 69 clevidipine 69 investigational humanized monoclonal antibody 69 orally bioavailable 69 immune modulatory 69 chemopreventive agent 69 LHRH agonists 69 rituximab Rituxan 69 CEQ# 69 decitabine 69 AQ4N 69 PARP inhibition 69 allogeneic HSCT 69 Sym# 68 ERalpha 68 neurologic progression 68 dacarbazine DTIC 68 Phase 1b clinical trials 68 omega interferon 68 dimeglumine 68 Gemzar gemcitabine 68 pharmacodynamic parameters 68 NS#/#A protease 68 Pathway Inhibitor 68 Pimavanserin 68 TREANDA 68 gemcitabine chemotherapy 68 sorafenib Nexavar ® 68 recombinant tissue plasminogen 68 flutamide 68 TRO# 68 alfa 2a 68 argatroban 68 Trastuzumab 68 Phase Ib study 68 multiple myeloma MM 68 elastase 68 Voreloxin 68 vinorelbine tartrate 68 oral rivaroxaban 68 rALLy clinical trial 68 Nexavar sorafenib 68 IFN α 68 miglustat 68 EGFR HER2 68 null responder 68 Xeloda ® 68 unresectable tumors 68 EGFR TKI 68 GTC recombinant human 68 STRIDE PD 68 HuMax 68 dasatinib Sprycel 68 Factor VIIa 68 Oral NKTR 68 eniluracil 68 tubulin inhibitor 68 lintuzumab SGN 68 pathophysiological effects 68 SAR# [004] 68 bleomycin 68 Elotuzumab 68 Diabetic Macular Edema 68 ALA PDT 68 chemotherapeutic regimen 68 Intravenous CP 68 ADP receptor antagonist 68 chimeric monoclonal antibody 68 Gemzar ® 68 Aurora Kinase 68 Randomized Phase 68 nucleotide analog 68 anthracycline taxane 68 florbetaben 68 Chronic Lymphocytic Leukemia CLL 68 AKT inhibitor 68 pharmacologically active isomer 68 Quinamed 68 selectively inhibited 68 imetelstat 68 IgG1 monoclonal antibody 68 GSTP1 68 paclitaxel Taxol 68 pharmacodynamic effects 68 tumor necrosis 68 #F FDG PET 68 Metastatic Melanoma 68 Rigel R# 68 MYLOTARG 68 Prolongs Survival 68 axitinib 68 Clusterin 68 ancrod 68 dose cohort 68 CHOP chemotherapy 68 oral deforolimus 68 synthetic retinoid 68 irbesartan 68 bovine thrombin 68 ERK1 2 68 azacitidine 68 IMiDs ® 68 EDEMA3 trial 68 FOLOTYN ® 68 Blinatumomab 68 Mg Usa 68 docetaxel chemotherapy 68 Novel Oral 68 aspirin clopidogrel 68 Xcytrin R 68 bortezomib Velcade ® 68 ATACAND 68 metastatic neuroendocrine tumors 68 colorectal liver metastases 68 haematologic malignancies 68 inhibitor RG# 68 amifostine 68 Vimpat R 68 HMG CoA reductase inhibitors 68 Immunotherapeutic 68 CINTREDEKIN BESUDOTOX 68 Atypical Hemolytic Uremic Syndrome 68 eritoran 68 systemically administered 68 Bevacizumab 68 DFMO 68 Proellex TM 68 vandetanib 68 immune modulator 68 IFN beta 68 anti androgen 68 IV Busulfex 68 OMP #M# 68 Antiangiogenic 68 adriamycin 68 PROCHYMAL 68 myopathy rhabdomyolysis 68 idraparinux 68 SCCHN 68 canakinumab 68 Peginterferon alfa 2b 68 Lenalidomide 68 effector function 68 ALK inhibitor 68 Evoltra ® 68 Zorbtive TM 68 taxane chemotherapy 68 IMC #B 68 Ceflatonin 68 rufinamide 68 placebo controlled clinical 68 calcineurin inhibitors 68 Tasimelteon 68 PEGylated anti 68 Tesmilifene 68 relapsed multiple myeloma 68 ThermoDox ® clinical 68 ISTODAX 68 antiarrhythmic 68 biliary tract cancer 68 Ecallantide 68 SCIg 68 diabetic neuropathic pain 68 TELINTRA 68 cis retinoic acid 68 BCG refractory 68 immunomodulator 68 ziconotide 68 initiated Phase Ib 68 THR beta agonist 68 GnRH agonists 68 gemcitabine Gemzar ® 68 polycythemia vera essential thrombocythemia 68 gemcitabine carboplatin 68 ARIKACE ™ 68 REMINYL ® 68 renal cell carcinomas 68 potentially hepatotoxic 68 Estrogen Receptor 68 Neupogen ® 68 bevacizumab Avastin 68 Personalized Immunotherapy 68 BAY #-# 68 adjuvant cisplatin 68 TRAIL R2 68 Xcellerated T Cells 68 virus HCV protease inhibitor 68 DAPT 68 motesanib 68 reduce serum phosphate 68 DermaVir Patch 68 Dapagliflozin 68 estrogen receptor antagonist 68 esophageal candidiasis 68 investigational monoclonal antibody 68 Endometrial 68 viral kinetics 68 Zarnestra 68 mycophenolic acid 68 cetuximab Erbitux ® 68 amrubicin 68 R#/MEM # 68 TORISEL TM 68 MyVax R 68 LT NS# 68 intravenous cyclophosphamide 68 BR.# 68 Cotara ® 68 mg kg dose 68 #F FDG 68 efaproxiral 68 NP2 Enkephalin 68 HDACi 68 Myelodysplastic Syndrome MDS 68 Aviptadil 68 Aurora kinase 68 HER2 ErbB2 68 nucleotide analogue 68 basiliximab 68 ACTEMRA TM 68 pioglitazone HCl 68 RG# [001] 68 secretin 68 TTF Therapy 68 deforolimus 68 Recombinant Human 68 phase IIa clinical 68 JAK inhibitors 68 Androxal TM 68 REG1 68 Trabectedin 68 RSD# oral 68 Virologic 68 cannabinor 68 Pharmacokinetics PK 68 pharmacokinetic interactions 68 opioid induced bowel dysfunction 68 candesartan cilexetil 68 Panzem R 68 Camptosar ® 68 OMNARIS HFA 68 TACI Ig 68 CBLC# 68 crizotinib PF # 68 cobiprostone 68 phase Ib 68 rtPA 68 IL# PE#QQR 68 Rituxan rituximab 68 CALGB # [002] 68 DITPA 68 Targretin capsules 68 Golimumab 67 salmeterol fluticasone 67 KRN# 67 OvaRex ® MAb 67 lanreotide 67 PI3K/Akt pathway inhibitor 67 octreotide LAR 67 tumor xenograft models 67 ANAVEX #-# [001] 67 hormone LHRH antagonist 67 APTIVUS 67 phase IIb study 67 Exherin TM 67 carboplatin paclitaxel 67 Lp PLA 2 67 oxypurinol 67 INCB# [003] 67 cortisol synthesis 67 reslizumab 67 oral mTOR inhibitor 67 Alequel 67 Fondaparinux 67 HepaMate 67 imatinib Gleevec ® 67 AEGR 67 chemosensitivity 67 Liposomal 67 AAG geldanamycin analog 67 lintuzumab 67 midstage clinical 67 PEGylated interferon 67 Cloretazine ® 67 tyrosine kinase inhibitor 67 paclitaxel poliglumex 67 transcranial Doppler ultrasound 67 cytostatic 67 alpha interferons 67 PEGylated Fab fragment 67 GSK# [001] 67 Phase IIb III 67 eosinophilic asthma 67 CA9 SCAN 67 dacetuzumab 67 anastrazole 67 refractory acute myeloid 67 gastrointestinal stromal tumors GIST 67 2A receptor agonist 67 beta interferons 67 Cremophor 67 sodium thiosulfate STS 67 TYKERB 67 Kinoid 67 chronic thromboembolic pulmonary 67 Antigen Specific 67 pharmacodynamic markers 67 Campath alemtuzumab 67 IMiDs ® compound 67 Insegia 67 MNTX 67 5alpha reductase 67 catheter occlusion 67 Fludarabine 67 Fibrillex TM 67 VitiGam 67 Intervention Effectiveness 67 dopamine D2 67 humanized antibody 67 Eribulin 67 tenofovir emtricitabine 67 ospemifene 67 ZD# [001] 67 de novo kidney transplant 67 Vascugel 67 receiving immunosuppressive therapy 67 Allovectin 7 ® 67 FOLFOX6 67 Kahalalide F 67 JAK inhibitor 67 farletuzumab 67 EndoTAGTM 1 67 mediated inhibition 67 lapatinib Tykerb 67 Neuradiab 67 recurrent NSCLC 67 Hycamtin ® 67 mTOR mammalian target 67 Allovectin 7 67 LHRH receptor positive 67 talabostat 67 Carfilzomib 67 nonsmall cell lung cancer 67 idarubicin 67 myeloid metaplasia 67 TLR9 agonist 67 CXB# 67 malignant ascites 67 Melphalan 67 Gamunex C 67 immunomodulatory properties 67 imatinib Gleevec 67 piperacillin tazobactam 67 Cimzia TM 67 eribulin mesylate 67 EP #R 67 antiarrhythmic drug 67 VEGF inhibitors 67 mGluR5 NAM 67 Preclinical studies suggest 67 capecitabine Xeloda 67 Naive Patients 67 Catena ® 67 relapsing multiple sclerosis 67 NEUMUNE 67 recurrent metastatic 67 YONDELIS R 67 Paraplatin ® 67 EGFR TKIs 67 cinacalcet 67 mGlu2 3 67 Interferon alpha 67 hypereosinophilic syndrome 67 induces apoptosis 67 Maribavir 67 TAXOTERE R 67 Aptivus ® 67 neoadjuvant treatment 67 cardiac contractility 67 methylnaltrexone bromide 67 PegIFN RBV 67 pretransplant 67 OvaRex MAb 67 G#DT 67 aflibercept VEGF Trap 67 endometrial hyperplasia 67 luteinizing hormone releasing 67 Solid Tumors 67 olmesartan 67 Eculizumab 67 sulindac 67 hematopoietic cancers 67 IMP# 67 dose melphalan 67 Pralatrexate 67 herpetic keratitis 67 sunitinib Sutent ® 67 Initiates Clinical 67 Virulizin ® 67 accumulate preferentially 67 JVRS 67 sulodexide 67 dual endothelin receptor antagonist 67 radiolabeled monoclonal antibody 67 Phase IIb clinical trials 67 neuroinflammatory 67 Severe Sepsis 67 Rebif ® 67 Varespladib 67 TO AVOID PREGNANCY WHILE 67 SNT-MC#/idebenone 67 non nucleoside inhibitor 67 efalizumab 67 R sorafenib tablets 67 cyclophosphamide Cytoxan 67 Navelbine R 67 mRCC 67 metastatic bladder 67 SERMs 67 indibulin 67 epirubicin 67 Cell Lymphoma CTCL 67 pentostatin 67 metastatic hormone refractory 67 Safinamide 67 small molecule tyrosine 67 NEUPOGEN 67 tipifarnib 67 Bayer HealthCare Onyx Pharmaceuticals 67 drug zotarolimus 67 xanthine oxidase inhibitor 67 vivo potency 67 Tanespimycin 67 HER2 expression 67 motesanib diphosphate 67 Oral Fingolimod 67 comparator arm 67 HuMax CD4 67 ACZ# 67 urocortin 2 67 NAVISTAR R 67 SUTENT ® 67 nucleoside analog 67 iniparib BSI 67 Ixempra 67 intracoronary 67 thrombin receptor 67 ALN TTR 67 concurrent chemoradiation 67 telomerase inhibition 67 atacicept 67 Proxinium TM 67 Pafuramidine 67 D aspartate NMDA receptor 67 triphendiol 67 novel histone deacetylase 67 alpha#beta# integrin 67 Lubiprostone 67 BMS# 67 aminolevulinic acid 67 PDX pralatrexate 67 mTOR inhibitor 67 Romidepsin 67 temozolomide TMZ 67 LEUKINE 67 Anthracycline 67 non resectable metastatic 67 Actimmune ® 67 CYP#A# CYP#D# 67 CCR5 mAb 67 active comparator 67 APTIVUS ritonavir 67 cutaneous T 67 pharmacodynamic profile 67 PROSTASCINT R 67 achieved CCyR 67 mTOR inhibition 67 RoACTEMRA 67 TNFa 67 gemtuzumab ozogamicin 67 HIF PHI 67 renal toxicity 67 monoclonal anti 67 severe neutropenia 67 blinded randomized placebo controlled 67 radiolabeled 67 ganetespib 67 MYDICAR ® 67 TEMODAL 67 mutated KRAS gene 67 Ocrelizumab 67 antibody MT# 67 TLR9 agonists 67 Raptiva R 67 baseline LDH 67 mouse xenograft models 67 Panzem ® 67 antineoplastic 67 CCX# 67 histone deacetylase 67 dosage regimens 67 solithromycin 67 Prestara 67 oral ridaforolimus 67 endothelin antagonists 67 recurrent malignant glioma 67 HCV SPRINT 67 Chemoradiation 67 lumiliximab 67 Pegylated Liposomal Doxorubicin 67 Inhalation Solution 67 azilsartan medoxomil 67 Bicalutamide 67 antitumoral 67 hoFH 67 Annamycin 67 Mylotarg 67 Filgrastim 67 Mitomycin C 67 Glypromate 67 dosing cohort 67 plasmid encoding 67 trastuzumab DM1 67 myeloproliferative diseases 67 Afatinib 67 romidepsin 67 vitro cytotoxicity 67 anticancer activity 67 Parathyroid Hormone 67 NATRECOR ® 67 prokinetic agent 67 Phase 2b Clinical Trial 67 Cytochrome P# 67 essential thrombocythemia ET 67 pegylated interferon alfa 2b 67 Dabigatran etexilate 67 dose escalation clinical 67 ONTAK 67 Alkeran 67 Subgroup analysis 67 allogeneic stem cell 67 PROSTVAC VF 67 VEGF receptor 67 plus prednisone prednisolone 67 protein tyrosine phosphatase 1B 67 Protexia ® 67 incyclinide 67 Gefitinib 67 selective antagonist 67 Diffuse Large B 67 alkylating 67 ONCONASE R 67 evaluating Xcytrin 67 vismodegib 67 ibritumomab tiuxetan 67 Denufosol 67 rt PA 67 XYOTAX TM 67 Saforis 67 Amphinex ® 67 Taxol ® 67 BCR ABL inhibitor 67 IgG1 antibody 67 MAGE A3 67 SinuNase ™ 67 nephrotoxicity 67 eTag assays 67 Vidofludimus 67 PHX# 67 MEK Inhibitor 67 Yondelis ® 67 EXJADE 67 Retreatment 67 ExTRACT TIMI 67 MGUS 67 hereditary deficiency 67 HSP# inhibitor 67 colorectal adenoma 67 Silodosin 67 B7 H3 67 treat benign prostatic 67 TBC# 67 Alocrest 67 Allogeneic 67 Genasense ® oblimersen 67 androgen suppression 67 plasma kallikrein 67 ON #.Na 67 QTc prolongation 67 Etoposide 67 Anti VEGF 66 xenograft models 66 AMEVIVE 66 Hepatotoxicity 66 Dendritic Cells 66 acid phosphatase PAP 66 edifoligide 66 factor Xa 66 Phase IIA 66 HMG CoA reductase inhibitor 66 Iloperidone 66 aprepitant 66 anticancer agent